Bris­tol My­ers gets its first GI drug ap­proval, and it comes from a long­time Cel­gene MS pro­gram

A for­mer long­time Cel­gene pro­gram that saw a bumpy road to ap­proval has picked up a new OK, with its new own­ers at Bris­tol My­ers Squibb shep­herd­ing it to a win in ul­cer­a­tive col­i­tis.

The FDA ap­proved ozan­i­mod in UC on Thurs­day af­ter­noon, Bris­tol My­ers an­nounced, be­com­ing what the Big Phar­ma said is the first S1P re­cep­tor mod­u­la­tor to treat the dis­ease. The drug will use the same brand name of Zeposia as in its orig­i­nal in­di­ca­tion of mul­ti­ple scle­ro­sis in the re­lapsed set­ting. Thurs­day’s ap­proval al­so marks Bris­tol My­ers’ first GI drug to hit the mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.